Scarica l'app Stockscreener
2.01
4.29%
-0.09
Dopo l'orario di chiusura:
1.76
-0.25
-12.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.10
Aprire:
$2.15
Volume 24 ore:
48,408
Relative Volume:
0.74
Capitalizzazione di mercato:
$9.21M
Reddito:
$468.00K
Utile/perdita netta:
$-10.34M
Rapporto P/E:
-0.2851
EPS:
-7.05
Flusso di cassa netto:
$-8.94M
1 W Prestazione:
-28.21%
1M Prestazione:
-20.24%
6M Prestazione:
-26.64%
1 anno Prestazione:
-65.19%
Intervallo 1D:
$1.95
$2.15
Intervallo di 1 settimana:
$1.95
$2.7647
Portata 52W:
$1.625
$6.15
Biocardia Inc Stock (BCDA) Company Profile
Nome
Biocardia Inc
Settore
Industria
Telefono
650-226-0123
Indirizzo
320 SOQUEL WAY, SUNNYVALE, CA
Confronta BCDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
19.95 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.16 | 337.66M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.265 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.25 | 139.95M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
10.50 | 137.23M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-16 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Borsa (BCDA) Ultime notizie
Biocardia CEO Peter Altman buys $2,435 in company stock - Investing.com
Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $2,688 in common stock - Investing.com India
Trial Results Show Autologous Cell Therapy Improves Survival, QOL and Reduces Cardiac Events in Distressed Heart Failure Patients - Diagnostic and Interventional Cardiology
Financial Analysis: BioCardia Inc (BCDA)’s Ratios Unveil Key Insights - DWinneX
BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Call Transcript - Insider Monkey
BioCardia Clarifies Timing for CardiAMP-HF Results Call - MSN
BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... - Yahoo Finance
ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains - Yahoo
BioCardia reports promising two-year CardiAMP trial results By Investing.com - Investing.com South Africa
Earnings call transcript: BioCardia Q4 2024 sees reduced expenses, stock down - Investing.com India
BioCardia Phase 3 CARDIAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years - HMP Global Learning Network
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today - Barchart.com
Critical CardiAMP-HF 2-Year Data Reveal: Key Findings Presentation Today - Stock Titan
BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint - MarketScreener
BioCardia reports promising two-year CardiAMP trial results - Investing.com
BioCardia Reports Positive Phase 3 CardiAMP-HF Results - TipRanks
Breakthrough Heart Failure Treatment Shows 47% Death Risk Reduction in Phase 3 Trial - Stock Titan
BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Beating Heart Patch Market Projected To Witness Substantial - openPR.com
BioCardia Reports 2024 Business Highlights and Financial Results - The Manila Times
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings - GuruFocus
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - The Manila Times
BioCardia, Inc. to Report 2024 Financial Results and Host Conference Call Following CardiAMP-HF Trial Presentation - Nasdaq
SBA Communications (SBAC) Gets a Buy from Barclays - The Globe and Mail
MindMed Appoints Matt Wiley as Chief Commercial Officer - The Globe and Mail
Reviewing BioCardia (NASDAQ:BCDA) & Moderna (NASDAQ:MRNA) - Defense World
UiPath (PATH) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
BioCardia secures new Japanese patent for heart therapy delivery By Investing.com - Investing.com Australia
BioCardia Gets Patent in Japan for Helix Biotherapeutic Delivery System -March 10, 2025 at 02:53 pm EDT - Marketscreener.com
BioCardia secures new Japanese patent for heart therapy delivery - Investing.com
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System - The Manila Times
BioCardia announces Japanese patent for Helix system - TipRanks
BioCardia Wins Patent Protection in Japan for Novel Heart Therapy System - StockTitan
BioCardia director Simon Stertzer acquires $2,450 in stock By Investing.com - Investing.com Australia
BioCardia director Simon Stertzer acquires $2,450 in stock - Investing.com
Director’s Bold Move: Major Stock Purchase Signals Confidence in BioCardia - TipRanks
Biocardia director Simon Stertzer acquires $88,064 in stock By Investing.com - Investing.com South Africa
Biocardia director Simon Stertzer acquires $88,064 in stock - Investing.com India
Biocardia CEO Peter Altman buys $1,055 in company stock - Investing.com
BioCardia Announces Primary Data Freeze For CardiAMP HF Phase 3 Trial For ACC 2025 Presentation - Nasdaq
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions - The Manila Times
BioCardia wraps up Phase 3 CardiAMP HF study data - Investing.com India
BioCardia finishes data freezing in heart failure therapy study for presentation - TipRanks
BioCardia Completes Source Data Verification for Phase 3 CardiAMP HF Study on Heart Failure Treatment - Nasdaq
BioCardia Announces Primary Outcome Measures Data Freeze in - GlobeNewswire
Will BioCardia's Cell Therapy Revolutionize Heart Failure Treatment? Phase 3 Data Coming Soon - StockTitan
BioCardia completes enrollment for heart therapy trial By Investing.com - Investing.com Canada
BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) - The Manila Times
Biocardia Inc Azioni (BCDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):